| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA940: Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) |
|
Medicine details |
|
| Medicine name | ravulizumab (Ultomiris®) |
| Formulation | intravenous infusion |
| Reference number | 4940 |
| Indication | Add-on to standard therapy for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody-positive |
| Company | Alexion Pharma UK Ltd |
| BNF chapter | Immunological products & vaccines |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 30/09/2022 |
| NICE guidance | TA940: Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) |